secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2026-07-02T14:37:20+00:00
Accession:  0001437749-26-022415
Event type: debt
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma extends revolving credit line to April 2027, enters $250K equipment note
--------------------------------------------------------------------------------

- Revolving line of credit extended to April 14, 2027; maximum principal remains $4,000,000.
- New $250,000 Convertible Line of Credit Note (Daily SOFR) for equipment/vehicles replaces matured $500,000 note.
- Interest on new note: Daily SOFR + 250 bps before conversion; after conversion, Daily SOFR or fixed rate at Bank's option.
- Amendment fee of $4,000 and legal fees of $2,500 paid to PNC Bank as conditions to effectiveness.
- Borrower reaffirms all security agreements, liens, and representations; no event of default exists.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926022415/0001437749-26-022415-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774926022415/inbp20260630_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-022415

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer